TrialInvestigational new drugs2003

Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer.

Christian Dittrich et al.PubMed ↗Publisher ↗

No numbers read from the abstract.